The New Jersey, US capsule maker said it had replicated micro-dosing operations at Xcelience's facility in Tampa Florida at the French site in order to be closer to European customers.
Amit Patel, President, Capsugel Dosage Form Solutions said: "By leveraging best practices pioneered by Xcelience, an array of Xcelodose technologies and our high-containment capability, we have further strengthened our speed-to-product toolkit.”
Xcelience provides specialized clinical trial manufacturing and supply services for a broad range of solid dosage forms, as well as development and manufacturing for specialized products such as highly potent and controlled substance compounds.
Capsugel bought Xcelience in December last year in a deal that expanded the dosage form solutions business it launched in February 2013.
The Xcelience acquisition, like that of Powdersize that it bought at the same time, are part of the strategy Capsugel has followed since it entered the dosage form solutions space.
In March 2013 Capsugel acquired Encap. The following October it bought Bend Research.
Capsugel said it plans to continue innovating and expanding its micro-dosing technology and service offering.
Takeover or IPO?
In April Reuters reported last week that Capsugel is "preparing to explore a sale or an initial public offering (IPO)" suggesting that Danaher, 3M, Becton-Dickinson, Thermo Fisher Scientific, Bayer and Catalent.
Capsugel's owner US private equity investor Kohlberg Kravis Roberts (KKR) - which acquired the firm from Pfizer in 2011 – has not commented on the report.